Anaplastic thyroid cancer: current state of the problem
P. A. Nikiforovich,
K. Yu. Slashchuk,
N. I. Timofeeva,
A. P. Polyakov,
I. V. Sleptsov,
M. V. Reinberg,
R. A. Chernikov https://doi.org/10.21294/1814-4861-2025-24-2-133-143
Abstract
Objective: to summarize current data on anaplastic thyroid cancer (ATC), one of the most aggressive forms of solid tumors. Material and Methods. A scientific literature review was conducted using the Medline, Cochrane Library, and E-library databases, primarily focusing on studies from the last 10 years. Out of 153 articles, 45 were selected for this review. Results. The primary clinical manifestations of ATC are associated with compression of structures in the neck, rapid growth, and the development of distant metastases. Although surgery remains the mainstay of treatment, it is often unfeasible due to the advanced stage of cancer at the time of diagnosis. Targeted therapy for BRAFV600E-muted ATC shows encouraging results and is considered a promising strategy for improving survival outcomes. Conclusion. This review highlights the importance of a multidisciplinary approach to the management of ATC, with a focus on surgery and neoadjuvant therapy. Neoadjuvant therapy may improve the prognosis for patients with unresectable tumors at the time of diagnosis. Further research is required to refine optimal treatment strategies and enhance the efficacy of existing therapies.
Keywords
About the Authors
P. A. Nikiforovich
Endocrinology Research Center
Russian Federation
Russian Federation
Petr A. Nikiforovich, MD, PhD, Deputy Chief Physician for Oncology
Author ID (Scopus): 57209572659
11, Dmitriy Ulyanov St., Moscow, 117292
K. Yu. Slashchuk
Endocrinology Research Center
Russian Federation
Russian Federation
Konstantin Yu. Slashchuk, MD, PhD, Senior Researcher, Radionuclide Therapy Department
Author ID (Scopus): 57192192400
11, Dmitriy Ulyanov St., Moscow, 117292
N. I. Timofeeva
N.I. Pirogov Clinic of High Medical Technologies of Saint Petersburg State University
Russian Federation
Russian Federation
Natalia I. Timofeeva, MD, PhD, Surgeon, Endocrinologist, Oncologist, Surgical (Endocrinological) Department
Researcher ID (WOS): AAZ-1032-2021. Author ID (Scopus): 57215861367
154, Fontanka Emb., Saint Petersburg, 190103
A. P. Polyakov
P. Hertsen Moscow Oncology Research Institute, National Medical Research Radiological Centre of the Ministry of Health of Russia
Russian Federation
Russian Federation
Andrey P. Polyakov, MD, DSc, Professor, Head of the Microsurgery Department; Professor, Department of Oncology, Radiotherapy and Plastic Surgery; Professor, Department of Plastic Surgery with Ophthalmology , Peoples’ Friendship University of Russia (Moscow, Russia)
Author ID (Scopus): 57196050979
3, 2nd Botkinskiy proezd, Moscow, 125284
I. V. Sleptsov
N.I. Pirogov Clinic of High Medical Technologies of Saint Petersburg State University ; North-West Medical Centre
Russian Federation
Russian Federation
Ilya V. Sleptsov, MD, DSc, Professor, Head of the Endocrine Surgery Department; Head of the Endocrine Surgery Department; Chief Specialist of the Surgical (Endocrinology) Department
Researcher ID (WOS): F-1670-2019. Author ID (Scopus): 57216017997
154, Fontanka Emb., Saint Petersburg, 190103
124, Savushkina St., Saint Petersburg, 197374
M. V. Reinberg
Endocrinology Research Center
Russian Federation
Russian Federation
Maria V. Reinberg, MD, Postgraduate
Author ID (Scopus): 59076052500
11, Dmitriy Ulyanov St., Moscow, 117292
R. A. Chernikov
N.I. Pirogov Clinic of High Medical Technologies of Saint Petersburg State University
Russian Federation
Russian Federation
Roman A. Chernikov, MD, DSc, Head of Surgical (Endocrinological) Department, Surgeon, Oncologist
Researcher ID (WOS): AAZ-1549-2021. Author ID (Scopus): 57190294900
154, Fontanka Emb., Saint Petersburg, 190103
References
1. Baloch Z.W., Asa S.L., Barletta J.A., Ghossein R.A., Juhlin C.C., Jung C.K., LiVolsi V.A., Papotti M.G., Sobrinho-Simões M., Tallini G., Mete O. Overview of the 2022 WHO Classification of Thyroid Neoplasms. Endocr Pathol. 2022; 33(1): 27–63. doi: 10.1007/s12022-022-09707-3.
2. Nikiforov Y.E. Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocr Pathol. 2004; 15(4): 319–27. doi: 10.1385/ep:15:4:319.
3. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4): 225–49. doi: 10.3322/caac.20006.
4. Davies L., Welch H.G. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006; 295(18): 2164–67. doi: 10.1001/jama.295.18.2164.
5. Cancer Stat Facts: Thyroid Cancer: SEER National Cancer Institute [Internet]. [cited 01.08.2025]. URL: https://seer.cancer.gov/statfacts/html/thyro.html.
6. Landa I., Ibrahimpasic T., Boucai L., Sinha R., Knauf J.A., Shah R.H., Dogan S., Ricarte-Filho J.C., Krishnamoorthy G.P., Xu B., Schultz N., Berger M.F., Sander C., Taylor B.S., Ghossein R., Ganly I., Fagin J.A. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest. 2016; 126(3): 1052–66. doi: 10.1172/JCI85271.
7. Brierley J., Gospodarowicz M.K, Wittekind C. TNM Classification Of Malignant Tumours. 8th ed., Wiley-Blackwell, 2016. 272 p.
8. Ain K.B., Egorin M.J., DeSimone P.A. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid. 2000; 10(7): 587–94. doi: 10.1089/thy.2000.10.587.
9. Nel C.J., van Heerden J.A., Goellner J.R., Gharib H., McConahey W.M., Taylor W.F., Grant C.S. Anaplastic carcinoma of the thyroid: a clinicopathologic study of 82 cases. Mayo Clin Proc. 1985; 60(1): 51–58. doi: 10.1016/s0025-6196(12)65285-9.
10. Glaser S.M., Mandish S.F., Gill B.S., Balasubramani G.K., Clump D.A., Beriwal S. Anaplastic thyroid cancer: Prognostic factors, patterns of care, and overall survival. Head Neck. 2016; 38s1. doi: 10.1002/hed.24384.
11. Venkatesh Y.S., Ordonez N.G., Schultz P.N., Hickey R.C., Goepfert H., Samaan N.A. Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer. 1990; 66(2): 321–30. doi: 10.1002/1097-0142(19900715)66:2<321::aid-cncr2820660221>3.0.co;2-a.
12. Ganina C.A., Mahonin A.A., Vladimirova T.Ju. Current perspectives and treatment options for anaplastic thyroid cancer. Head and neck. Russian Journal. 2023; 11(1): 85–92 (in Russian). doi: 10.25792/HN.2023.11.1.85-92. EDN: VDAFGK.
13. Ciarallo A., Marcus C., Taghipour M., Subramaniam R.M. Value of Fluorodeoxyglucose PET/Computed Tomography Patient Management and Outcomes in Thyroid Cancer. PET Clin. 2015; 10(2): 265–78. doi: 10.1016/j.cpet.2014.12.009.
14. Nikiforovich P.A., Rumiantsev P.O., Sleptsov I.V., Ustinova T.V., Slashchuk K.Yu., Vorobyev S.L., Serzhenko S.S., Abrosimov A.Yu., Kudryavtseva A.V., Semenov A.A., Chernikov R.A., Polyakov A.A., Fedenko A.A., Bolotina L.V., Paychadze A.A., Trushin A.Y., Kaprin A.D., Zakharova G.S. Treatment of BRAFV600E positive anaplastic thyroid carcinoma: Case report. Siberian Journal of Oncology. 2020; 19(5): 131–44. (in Russian). doi: 10.21294/1814-4861-2020-19-5-131-144. EDN: UOBQYE.
15. Cunha C., Mousinho F., Saraiva C., Sequeira Duarte J. Follicular lymphoma of the thyroid and the role of core needle biopsy. Endocrinol Diabetes Metab Case Rep. 2023. doi: 10.1530/EDM-21-0196.
16. Bailey M.H., Tokheim C., Porta-Pardo E., et al. Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell. 2018; 174(4): 1034–35. doi: 10.1016/j.cell.2018.07.034. Erratum for: Cell. 2018; 173(2): 371–85. doi: 10.1016/j.cell.2018.02.060.
17. Lawless A.K., Kumar S., Bindra J., Sywak M., Chou A., Turchini J., Papachristos A., Wijewardene A., Sidhu S., Ahadi M., Tacon L., Glover A., Clark K., Tsang V., Pang L., Clifton-Bligh R.J., Robinson B., Gill A.J., Guminski A., Eade T., Gild M.L. Anaplastic thyroid cancer: A review of recent evidence and summary of an Australian institutional protocol. Asia Pac J Clin Oncol. 2024; 20(6): 681–89. doi: 10.1111/ajco.14106.
18. Deeken-Draisey A., Yang G.Y., Gao J., Alexiev B.A. Anaplastic thyroid carcinoma: an epidemiologic, histologic, immunohistochemical, and molecular single-institution study. Hum Pathol. 2018; 82: 140–48. doi: 10.1016/j.humpath.2018.07.027.
19. Wan S.K., Chan J.K., Tang S.K. Paucicellular variant of anaplastic thyroid carcinoma. A mimic of Reidel’s thyroiditis. Am J Clin Pathol. 1996; 105(4): 388–93. doi: 10.1093/ajcp/105.4.388.
20. Xu B., Fuchs T., Dogan S., Landa I., Katabi N., Fagin J.A., Tuttle R.M., Sherman E., Gill A.J., Ghossein R. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases. Thyroid. 2020; 30(10): 1505–17. doi: 10.1089/thy.2020.0086.
21. Carda C., Ferrer J., Vilanova M., Peydró A., Llombart-Bosch A. Anaplastic carcinoma of the thyroid with rhabdomyosarcomatous differentiation: a report of two cases. Virchows Arch. 2005; 446(1): 46–51. doi: 10.1007/s00428-004-1123-0.
22. Salvatore D., Celetti A., Fabien N., Paulin C., Martelli M.L., Battaglia C., Califano D., Monaco C., Viglietto G., Santoro M., Fusco A. Low frequency of p53 mutations in human thyroid tumours; p53 and Ras mutation in two out of fifty-six thyroid tumours. Eur J Endocrinol. 1996; 134(2): 177–83. doi: 10.1530/eje.0.1340177.
23. Cancer Genome Atlas Research Network: Agrawal N., Akbani R., Aksoy B.A., et al. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014; 159(3): 676–90. doi: 10.1016/j.cell.2014.09.050.
24. Foote R.L., Molina J.R., Kasperbauer J.L., Lloyd R.V., McIver B., Morris J.C., Grant C.S., Thompson G.B., Richards M.L., Hay I.D., Smallridge R.C., Bible K.C. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. Thyroid. 2011; 21(1): 25–30. doi: 10.1089/thy.2010.0220.
25. Volante M., Lam A.K., Papotti M., Tallini G. Molecular Pathology of Poorly Differentiated and Anaplastic Thyroid Cancer: What Do Pathologists Need to Know? Endocr Pathol. 2021; 32(1): 63–76. doi: 10.1007/s12022-021-09665-2.
26. Bible K.C., Kebebew E., Brierley J., Brito J.P., Cabanillas M.E., Clark T.J. Jr, Di Cristofano A., Foote R., Giordano T., Kasperbauer J., Newbold K., Nikiforov Y.E., Randolph G., Rosenthal M.S., Sawka A.M., Shah M., Shaha A., Smallridge R., Wong-Clark C.K. 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid. 2021; 31(3): 337–86. doi: 10.1089/thy.2020.0944. Erratum in: Thyroid. 2021; 31(10): 1606–7. doi: 10.1089/thy.2020.0944.correx.
27. Hölting T., Meybier H., Buhr H. Status of tracheotomy in treatment of the respiratory emergency in anaplastic thyroid cancer. Wien Klin Wochenschr. 1990; 102(9): 264–66.
28. Nilsson O., Lindeberg J., Zedenius J., Ekman E., Tennvall J., Blomgren H., Grimelius L., Lundell G., Wallin G. Anaplastic giant cell carcinoma of the thyroid gland: treatment and survival over a 25-year period. World J Surg. 1998; 22(7): 725–30. doi: 10.1007/s002689900460.
29. Prasongsook N., Kumar A., Chintakuntlawar A.V., Foote R.L., Kasperbauer J., Molina J., Garces Y., Ma D., Wittich M.A.N., Rubin J., Richardson R., Morris J., Hay I., Fatourechi V., McIver B., Ryder M., Thompson G., Grant C., Richards M., Sebo T.J., Rivera M., Suman V., Jenkins S.M., Smallridge R.C., Bible K.C. Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer. J Clin Endocrinol Metab. 2017; 102(12): 4506–14. doi: 10.1210/jc.2017-01180.
30. Tennvall J., Lundell G., Wahlberg P., Bergenfelz A., Grimelius L., Akerman M., Hjelm Skog A.L., Wallin G. Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer. 2002; 86(12): 1848–53. doi: 10.1038/sj.bjc.6600361.
31. Kebebew E., Greenspan F.S., Clark O.H., Woeber K.A., McMillan A. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer. 2005; 103(7): 1330–35. doi: 10.1002/cncr.20936.
32. Kwon J., Kim B.H., Jung H.W., Besic N., Sugitani I., Wu H.G. The prognostic impacts of postoperative radiotherapy in the patients with resected anaplastic thyroid carcinoma: A systematic review and meta-analysis. Eur J Cancer. 2016; 59: 34–45. doi: 10.1016/j.ejca.2016.02.015.
33. Choynzonov E.L., Lisin V.A., Gribova O.V., Novikov V.A., Startseva Zh.A. Neutron therapy for head and neck cancer. Moscow, 2021. 328 p. (in Russian). ISBN 978-5-907366-38-1. EDN: ZRLMKP.
34. Nikiforovich P.A., Polyakov A.P., Sleptsov I.., Boyko N.S., Gronskaya Yu.A., Timofeeva N., Chernikov R.A. Targeted therapy of anaplastic thyroid cancer. Head and Neck Tumors (HNT). 2022; 12(4): 33–38. (in Russian). doi: 10.17650/2222-1468-2022-12-4-33-38. EDN: CFFEPX.
35. Pozdeyev N., Gay L.M., Sokol E.S., Hartmaier R., Deaver K.E., Davis S., French J.D., Borre P.V., LaBarbera D.V., Tan A.C., Schweppe R.E., Fishbein L., Ross J.S., Haugen B.R., Bowles D.W. Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers. Clin Cancer Res. 2018; 24(13): 3059–68. doi: 10.1158/1078-0432.CCR-18-0373.
36. Maniakas A., Dadu R., Busaidy N.L., Wang J.R., Ferrarotto R., Lu C., Williams M.D., Gunn G.B., Hofmann M.C., Cote G., Sperling J., Gross N.D., Sturgis E.M., Goepfert R.P., Lai S.Y., Cabanillas M.E., Zafereo M. Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000–2019. JAMA Oncol. 2020; 6(9): 1397–404. doi: 10.1001/jamaoncol.2020.3362.
37. Subbiah V., Kreitman R.J., Wainberg Z.A., Cho J.Y., Schellens J.H.M., Soria J.C., Wen P.Y., Zielinski C., Cabanillas M.E., Urbanowitz G., Mookerjee B., Wang D., Rangwala F., Keam B. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. J Clin Oncol. 2018; 36(1): 7–13. doi: 10.1200/JCO.2017.73.6785.
38. Baek S.K., Lee M.C., Hah J.H., Ahn S.H., Son Y.I., Rho Y.S., Chung P.S., Lee Y.S., Koo B.S., Jung K.Y., Lee B.J. Role of surgery in the management of anaplastic thyroid carcinoma: Korean nationwide multicenter study of 329 patients with anaplastic thyroid carcinoma, 2000 to 2012. Head Neck. 2017; 39(1): 133–39. doi: 10.1002/hed.24559.
39. Iyer P.C., Dadu R., Ferrarotto R., Busaidy N.L., Habra M.A., Zafereo M., Gross N., Hess K.R., Gule-Monroe M., Williams M.D., Cabanillas M.E. Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma. Thyroid. 2018; 28(1): 79–87. doi: 10.1089/thy.2017.0285.
40. Kloos R.T., Ringel M.D., Knopp M.V., Hall N.C., King M., Stevens R., Liang J., Wakely P.E. Jr, Vasko V.V., Saji M., Rittenberry J., Wei L., Arbogast D., Collamore M., Wright J.J., Grever M., Shah M.H. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol. 2009; 27(10): 1675–84. doi: 10.1200/JCO.2008.18.2717.
41. Исаев П.А., Полькин В.В., Северская Н.В., Ильин А.А., Плугарь А.К., Иванов С.А., Каприн А.Д. Результаты лечения больных недифференцированной карциномой щитовидной железы. Опухоли головы и шеи. 2022; 12(4): 17–24. doi: 10.17650/2222-1468-2022-12-4-17-24. EDN: IZYVTI.
42. Iwasaki H., Toda S., Suganuma N., Murayama D., Nakayama H., Masudo K. Lenvatinib vs. palliative therapy for stage IVC anaplastic thyroid cancer. Mol Clin Oncol. 2020; 12(2): 138–43. doi: 10.3892/mco.2019.1964.
43. Chintakuntlawar A.V., Rumilla K.M., Smith C.Y., Jenkins S.M., Foote R.L., Kasperbauer J.L., Morris J.C., Ryder M., Alsidawi S., Hilger C., Bible K.C. Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study. J Clin Endocrinol Metab. 2017; 102(6): 1943–50. doi: 10.1210/jc.2016-3756.
44. Adam P., Kircher S., Sbiera I., Koehler V.F., Berg E., Knösel T., Sandner B., Fenske W.K., Bläker H., Smaxwil C., Zielke A., Sipos B., Allelein S., Schott M., Dierks C., Spitzweg C., Fassnacht M., Kroiss M. FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale. Front Endocrinol (Lausanne). 2021; 12. doi: 10.3389/fendo.2021.712107.
45. Capdevila J., Wirth L.J., Ernst T., Ponce Aix S., Lin C.C., Ramlau R., Butler M.O., Delord J.P., Gelderblom H., Ascierto P.A., Fasolo A., Führer D., Hütter-Krönke M.L., Forde P.M., Wrona A., Santoro A., Sadow P.M., Szpakowski S., Wu H., Bostel G., Faris J., Cameron S., Varga A., Taylor M. PD-1 Blockade in Anaplastic Thyroid Carcinoma. J Clin Oncol. 2020; 38(23): 2620–27. doi: 10.1200/JCO.19.02727.
46. Dierks C., Seufert J., Aumann K., Ruf J., Klein C., Kiefer S., Rassner M., Boerries M., Zielke A., la Rosee P., Meyer P.T., Kroiss M., Weißenberger C., Schumacher T., Metzger P., Weiss H., Smaxwil C., Laubner K., Duyster J., von Bubnoff N., Miething C., Thomusch O. Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma. Thyroid. 2021; 31(7): 1076–85. doi: 10.1089/thy.2020.0322.
Review
For citations:
Nikiforovich P.A., Slashchuk K.Yu., Timofeeva N.I., Polyakov A.P., Sleptsov I.V., Reinberg M.V., Chernikov R.A. Anaplastic thyroid cancer: current state of the problem. Siberian journal of oncology. 2025;24(2):133-143. (In Russ.) https://doi.org/10.21294/1814-4861-2025-24-2-133-143
Views:
877
Email this article 
